SYRE earnings: real EPS beat/miss history, analyst consensus Buy, P/E -45.49. Updated 2026-07-23.
Spyre Therapeutics (SYRE) Research Hub
Spyre Therapeutics (SYRE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 90.6 USD (+4.22%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -45.49, market cap 6.03B. This hub links to the full technical, earnings and options research available for SYRE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 90.6 USD (+4.22%) |
| 52-week range | 80.79 USD – 110.18 USD |
| Trend regime | Range |
| 14-day RSI | 34 (Bearish) |
| Trailing P/E | -45.49 |
| Market cap | 6.03B |
| Dividend yield | 0.00% |
Available research for SYRE
Covered Call on SYRE: how it works, illustrative setup around the real 90.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SYRE: how it works, illustrative setup around the real 90.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SYRE: how it works, illustrative setup around the real 90.6 USD price, max profit/loss, breakeven and when to use it. Educational.
SYRE technical analysis: range, last 90.6 USD, RSI 34, 52w range 80.79 USD–110.18 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SYRE in?
Spyre Therapeutics (SYRE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SYRE in an uptrend or downtrend?
As of 2026-09-11, SYRE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SYRE's trailing P/E ratio?
SYRE's trailing P/E is -45.49, with a market cap of 6.03B. See the earnings research page for full valuation detail.